novo nordisk semaglutide vial (NOVOB) Shot Helps Teens Lose Weight: New EnglandJournal Study Novo Nordisk announced headline results

In people with obesity + Type 2 Diabetes, HbA1c reductions reached 2.2%, with dosedependent improvements in both weight and glycemia, positioning berobenatide as a potential cardiometabolic therapy

As understanding of obesity as a chronic medical condition continues to grow, treatments such as Wegovy HD are helping to expand the range of personalised options available to patients and healthcare professionals

Mild and temporary reactions like redness or discomfort at the site of injection have been reported

Long-term data is still evolving for both formulations

Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents)